Use of thrombin time to transition from dabigatran to intravenous unfractionated heparin in patients with acute kidney injury

Am J Health Syst Pharm. 2025 Sep 9;82(18):1022-1025. doi: 10.1093/ajhp/zxaf059.

Abstract

Purpose: This case series explores the use of thrombin time (TT) to transition 2 patients from dabigatran to unfractionated heparin (UFH) in the setting of acute kidney injury (AKI) and coagulopathy concerning for dabigatran accumulation.

Summary: Serial TT monitoring was employed until the value began to trend below 120 seconds, indicating ongoing drug clearance, at which point UFH was initiated. Patient 1 experienced rectal bleeding following initiation of UFH, while patient 2 experienced hemoglobin drops without an apparent bleeding source. No thrombotic events occurred during either hospitalization.

Conclusion: Individualized management remains paramount to balance bleeding and thrombotic risk based on patient-specific factors. Further research is warranted to validate the safety and efficacy of a TT-guided transition strategy and optimize protocols for hospitalized patients transitioning from dabigatran to UFH.

Keywords: coagulation assay; dabigatran; direct thrombin inhibitor; thrombin time; transition.

Publication types

  • Case Reports

MeSH terms

  • Acute Kidney Injury* / blood
  • Acute Kidney Injury* / complications
  • Acute Kidney Injury* / drug therapy
  • Aged
  • Aged, 80 and over
  • Anticoagulants* / administration & dosage
  • Anticoagulants* / adverse effects
  • Antithrombins* / administration & dosage
  • Antithrombins* / adverse effects
  • Dabigatran* / administration & dosage
  • Female
  • Hemorrhage / chemically induced
  • Heparin* / administration & dosage
  • Heparin* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Thrombin Time / methods

Substances

  • Dabigatran
  • Heparin
  • Antithrombins
  • Anticoagulants